Skip to main navigation Skip to search Skip to main content

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)
66 Downloads (Pure)
Original languageEnglish
Pages (from-to)3305-3313
Number of pages9
JournalQuality of Life Research
Volume29
Issue number12
DOIs
Publication statusPublished - 2020

Research programs

  • EMC ONWAR-01-58-02
  • EMC OR-01

Cite this